Related Experiment Video
Updated: May 4, 2026
07:13
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
1.1K
Vitamin K antagonists: beyond bleeding
1Division of Nephrology, Uniklinik RWTH Aachen, Aachen, Germany.
Seminars in Dialysis
|January 10, 2014
Summary
Warfarin, a common anticoagulant, poses significant risks for hemodialysis patients, including cardiovascular calcification and calciphylaxis. Careful consideration of these nontraditional side effects is crucial before prescribing vitamin K antagonists.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Warfarin is a widely used oral anticoagulant.
- Its use is frequent in hemodialysis (HD) patients due to high cardiovascular comorbidities.
- Warfarin use in dialysis patients with atrial fibrillation needs caution due to potential risks outweighing benefits.
Purpose of the Study:
- To summarize nontraditional side effects of coumarins (warfarin).
- To provide recommendations for vitamin K antagonist use in end-stage renal disease (ESRD) patients.
- To highlight considerations for warfarin in hemodialysis patients.
Main Methods:
- Literature review on warfarin side effects in ESRD patients.
- Analysis of clinical implications of nontraditional side effects.
- Synthesis of current evidence and guidelines.
Main Results:
- Warfarin can induce or accelerate cardiovascular calcifications.
- HD patients have a 10-fold increased risk of calciphylaxis with warfarin.
- Maintaining a target INR range is challenging in HD patients.
Conclusions:
- Nontraditional side effects of warfarin require special consideration in HD patients.
- The decision to prescribe vitamin K antagonists should weigh risks against benefits.
- New anticoagulants are promising but lack approval for ESRD patients.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:24Disorders of Hemostasis
2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:30Venous Thrombosis IV: Nursing Management
415
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415